-
Isotechnika Pharma and 3SBio Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
-
Isotechnika reports second quarter 2010 financial results
-
Lux Biosciences receives Complete Response letter from FDA for voclosporin
-
Pharma Watch: 3SBio, Isotechnika Partner on Voclosporin
-
Isotechnika lands China deal
-
Isotechnika Pharma signs $6m commercialization agreement for transplant organ rejection drug with 3SBio in China